KALA BIO (KALA)
NASDAQ:KALA
Want to see KALA full AI Analyst Report?
KALA Stock Chart & Stats
$0.62
-$0.34(-4.42%)
At close: 4:00 PM EST
$0.62
-$0.34(-4.42%)
Day’s Range― - ―
52-Week Range$2.10 - $1,030.00
Previous CloseN/A
Volume15.45K
Average Volume (3M)1.94M
Market Cap
$44.43M
Enterprise Value$47.14M
Total Cash (Recent Filing)$8.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding18,589,832
10 Day Avg. Volume624,022
30 Day Avg. Volume1,940,241
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)32.38
Price to Sales (P/S)0.00
P/FCF Ratio-7.08
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-872.96
Enterprise Value/Ebitda-1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-26.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exclusive AI Platform LicenseThe exclusive Researgency license creates a structural shift from one-off biotech projects to a potential recurring platform-as-a-service. An on-premises, data-sovereign offering targets underserved small/mid-cap R&D budgets, enabling durable revenue streams and differentiation versus cloud-centric rivals.
Debt Reduced To ZeroEliminating debt materially lowers financial risk and interest burden, improving flexibility to fund clinical programs or platform buildout. With no scheduled debt service, management can prioritize R&D and partnership investments, extending runway under adverse funding conditions.
Positive Equity TrendRising positive equity provides a cushion against losses and supports future capital raises on less dilutive terms. Combined with reduced leverage, it signals residual net assets that can absorb continued R&D spend while the company scales its AI platform and clinical programs.
Bears Say
Zero RevenueThe company currently has no product revenue, leaving operations fully dependent on financings. Lack of commercial cashflow means clinical progress and platform commercialization must bridge long development cycles, increasing execution and funding risk over the medium term.
Heavy Cash BurnPersistently negative operating and free cash flow, with accelerating TTM burn, creates a chronic financing requirement. Ongoing cash outflows constrain strategic optionality, risk dilutive raises, and can force partnership or asset-sales decisions that alter long-term strategy or economics.
Dilution From AI License DealThe Researgency deal includes immediate share issuance and future cash/share obligations, materially diluting existing holders and increasing financing pressure. While strategic, recurring payment terms and renewal-linked dilution could erode long-term shareholder value if revenue ramp is slower than expected.
KALA BIO News
KALA FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest stock price was $2.10 and its highest was $1030.00 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $44.43M.
When is KALA BIO’s upcoming earnings report date?
KALA BIO’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were KALA BIO’s earnings last quarter?
KALA BIO released its earnings results on May 19, 2026. The company reported -$0.136 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.136.
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO does not currently pay dividends.
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 18,589,832 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
KALA BIO reported an EPS of -$0.136 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.642%.
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in KALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
KALA BIO Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 40.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.36%
12-Months-Change
Fundamentals
Return on Equity
-1335.64%
Trailing 12-Months
Asset Growth
-74.47%
Trailing 12-Months
Company Description
KALA BIO
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Technical Analysis
Ownership Overview
3.97% Insiders
0.36% Mutual Funds
― Other Institutional Investors
95.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---